Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
A new study by Sandra Amaral and her team has found that children with chronic kidney disease (CKD), regardless of disease severity,...
Read Full NewsMRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.
Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.
Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.
A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.
1.
Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death
2.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
3.
The importance of breast cancer screening
4.
New imaging probe helps track prostate cancer and possibly treat it before resistance develops
5.
Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results
1.
Subarachnoid Hemorrhage: Emerging Insights into Pathophysiology and Future Management
2.
Personalized Cancer Vaccines and Neoantigen mRNA: A New Era in Oncology
3.
Chondroma: What it is and How it Affects Your Health
4.
Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications
5.
Exploring New Treatment Options for Hemophilia: A Journey into the Unknown
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge